Veraxa Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 45

Employees

  • Stock Symbol
  • VRXA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.11
  • (As of Friday Closing)

Veraxa General Information

Description

Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.

Contact Information

Website
veraxa.com
Formerly Known As
Velabs Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Im Neuenheimer Feld 584
  • 69120 Heidelberg
  • Germany
+49 06221
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences, Oncology
Corporate Office
  • Im Neuenheimer Feld 584
  • 69120 Heidelberg
  • Germany
+49 06221

Veraxa Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Veraxa Stock Performance

As of 13-Nov-2026, Veraxa’s stock price is $1.11. Its current market cap is $157M with 141M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.11 $1.15 $0.90 - $27.36 $157M 141M 264K -$0.57

Veraxa Financials Summary

As of 31-Dec-2025, Veraxa has a trailing 12-month revenue of $28.2K.

In Thousands,
USD 		TTM 31-Dec-2025 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
Revenue 28 28 0 0
EBITDA (78,245) (78,245) (30,524) (17,582)
Net Income (80,151) (80,151) (31,951) (18,405)
Total Assets 102,056 102,056 93,817 109,457
Total Debt 2,703 2,703 957 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Veraxa Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Veraxa‘s full profile, request access.

Request a free trial

Veraxa Patents

  • 43

    Total Documents Applications and Grants

  • Total Patents Families

  • 17

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

Veraxa Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026180750-A1 Bipartite targeting agent-payload conjugates Pending 28-Feb-2025
WO-2026139575-A1 Novel tco-functionalized glycan engineered immunoglobulin molecules, novel tco-functionalized saccharide compounds for preparing the same, and novel antibody payload conjugates Pending 23-Dec-2024
WO-2026132368-A1 Improved anti-cd3 antibodies Pending 20-Dec-2024
AU-2024300552-A1 Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same Pending 27-Jul-2023
EP-4750750-A1 Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same Pending 27-Jul-2023 C07C69/732
To view Veraxa’s complete patent history, request access »

Veraxa Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Veraxa Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Veraxa‘s full profile, request access.

Request a free trial

Veraxa Acquisitions (1)

Veraxa’s most recent deal was a Merger/Acquisition with Voyager Acquisition. The deal was made on 10-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Voyager Acquisition 10-Jun-2026 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Veraxa’s complete acquisitions history, request access »

Veraxa FAQs

  • When was Veraxa founded?

    Veraxa was founded in 2017.

  • Where is Veraxa headquartered?

    Veraxa is headquartered in Heidelberg, Germany.

  • What is the size of Veraxa?

    Veraxa has 45 total employees.

  • What industry is Veraxa in?

    Veraxa’s primary industry is Drug Discovery.

  • Is Veraxa a private or public company?

    Veraxa is a Public company.

  • What is Veraxa’s stock symbol?

    The ticker symbol for Veraxa is VRXA.

  • What is the current stock price of Veraxa?

    As of 13-Nov-2026 the stock price of Veraxa is $1.11.

  • What is the current market cap of Veraxa?

    The current market capitalization of Veraxa is $157M.

  • What is Veraxa’s current revenue?

    The trailing twelve month revenue for Veraxa is $28.2K.

  • What is Veraxa’s annual earnings per share (EPS)?

    Veraxa’s EPS for 12 months was -$0.57.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process